Related by context. All words. (Click for frequent words.) 70 metastatic renal cell 70 basal cell carcinoma BCC 69 Hepatocellular Carcinoma HCC 69 recurrent NSCLC 68 metastatic renal cell carcinoma 68 recurrent metastatic 68 gastric adenocarcinoma 68 carcinoid tumors 68 mRCC 68 recurrent glioblastoma 68 gastrointestinal stromal tumors GIST 68 advanced hepatocellular carcinoma 68 Gleevec resistant 68 relapsed MM 68 KRAS mutations occur 67 nonmetastatic 67 HER2 positive metastatic breast 67 biliary tract cancer 67 Cholangiocarcinoma 67 Malignant Melanoma 67 metastatic GIST 67 hepatocellular carcinoma HCC 67 recurrent glioblastoma multiforme 67 cisplatin chemotherapy 67 metastatic bladder 67 metastatic colorectal 67 invasive candidiasis 67 pancreatic NET 67 myelodysplastic myeloproliferative diseases 67 urothelial carcinoma 67 assessing T DM1 67 fallopian tube carcinoma 67 Fludara ® 67 pancreatic adenocarcinoma 66 leukemia AML 66 Chronic lymphocytic leukemia 66 metastatic colorectal cancer 66 HBeAg negative 66 pancreatic carcinoma 66 hepatocellular carcinoma 66 tumors GIST 66 malignant pleural mesothelioma 66 mCRC 66 ThermoDox R 66 nonsmall cell lung cancer 66 NMIBC 66 Kit CD# positive 66 renal cell carcinoma 66 candidemia 65 refractory metastatic colorectal cancer 65 squamous cell carcinoma SCC 65 stage IIIB 65 chronic HBV 65 Amrubicin 65 ovarian lung 65 colorectal carcinoma 65 non squamous 65 epithelial tumors 65 indolent NHL 65 Brain metastases 65 Chronic myeloid leukemia 65 malignant neoplasm 65 fallopian tube cancers 65 metastatic pancreatic 65 CYT# potent vascular disrupting 65 KRAS wild 65 Ophena TM 65 refractory prostate cancer 65 histologic subtype 65 SCCHN 65 unresectable stage 65 metastatic malignant 65 skeletal metastases 65 hormone refractory 65 Nexavar sorafenib 65 gastrointestinal stromal tumors 65 receptor tyrosine kinase inhibitor 65 castrate resistant prostate cancer 65 neuroendocrine cancers 65 osteosarcomas 65 Metastatic Colorectal Cancer 65 OPAXIO 65 non squamous NSCLC 65 NSCLC 65 Peginterferon alfa 2b 65 mCRC patients 65 carcinoid 65 gemcitabine chemotherapy 64 gastrointestinal stromal tumor GIST 64 systemic ALCL 64 vidofludimus 64 metastatic CRC 64 gastrointestinal stromal tumor 64 gastric carcinoma 64 HNSCC 64 recurrent colorectal cancer 64 platinum refractory 64 ACTEMRA TM 64 Irinotecan 64 Acute myeloid leukemia 64 liver metastasis 64 GISTs 64 FOLFOX6 64 plus gemcitabine 64 papillary renal cell carcinoma 64 AVASTIN 64 HER2 positive 64 neuroendocrine carcinoma 64 dasatinib Sprycel 64 non metastatic osteosarcoma 64 liver metastases 64 KRAS status 64 metastatic malignant melanoma 64 Cutaneous T 64 heavily pretreated 64 erlotinib Tarceva ® 64 endometrial hyperplasia 64 HeFH 64 p# biomarker 64 cell lymphoma CTCL 64 multiple myeloma MM 64 metastatic gastric 64 soft tissue sarcomas 64 lymphoid malignancies 64 metastatic hormone refractory 64 Squamous 64 carcinoma HCC 64 Hepatocellular Carcinoma 64 prostate cancer CRPC 64 LEUKINE 64 Telatinib 64 Glioblastoma Multiforme GBM 64 malignant ascites 64 Hormone Refractory Prostate Cancer 64 cirrhosis liver failure 64 adenocarcinomas 64 Combination REOLYSIN R 64 AA amyloidosis 64 leukemia ALL 64 metastatic carcinoma 64 treatment naïve genotype 64 Velcade bortezomib 64 follicular lymphoma FL 64 forodesine 64 colorectal cancer CRC 64 acute GvHD 64 breast pancreatic 64 gemcitabine carboplatin 64 Evoltra ® 64 cutaneous melanoma 64 nonalcoholic steatohepatitis NASH 63 acute myelogenous leukemia AML 63 gastric cancers 63 Tamibarotene 63 BR.# 63 FOLFIRI alone 63 recurrent glioblastoma multiforme GBM 63 opioid induced constipation OIC 63 relapsing remitting MS RRMS 63 breast carcinomas 63 Natalizumab 63 polycythemia vera essential thrombocythemia 63 neoplasia 63 EGFR mutation positive 63 metastatic RCC 63 systemic lupus erythematosus SLE 63 Aflibercept 63 bladder cancers 63 myelodysplastic syndrome MDS 63 ovarian carcinoma 63 palliative radiotherapy 63 Idiopathic Pulmonary Fibrosis 63 cetuximab Erbitux 63 phase IIb clinical 63 SPRYCEL ® 63 hepatocellular carcinomas 63 EGFR inhibitors 63 peritoneal carcinomatosis 63 invasive aspergillosis 63 Xanafide 63 Philadelphia Chromosome Positive 63 complement inhibitor eculizumab 63 Genasense ® 63 TTF Therapy 63 ORENCIA ® 63 Cell Lymphoma 63 gefitinib Iressa 63 elacytarabine 63 e antigen HBeAg 63 Soft Tissue Sarcoma 63 stage IIIb IV 63 prostate adenocarcinoma 63 K ras mutations 63 ToGA 63 BARACLUDE ® 63 Pemetrexed 63 Renal Cell Carcinoma RCC 63 tumor lysis syndrome 63 metastatic castrate resistant 63 BCG refractory 63 resistant hormone refractory 63 glioblastoma multiforme GBM 63 docetaxel Taxotere ® 63 chronic HBV infection 63 Papillary 63 Glioblastoma multiforme 63 leiomyomas 63 refractory ovarian cancer 63 minimally symptomatic 63 completely resected 63 breast carcinoma 63 TREANDA 63 Myelodysplastic Syndrome MDS 63 Candida infection 63 PANVAC VF 63 prostate carcinoma 63 CIN3 63 malignant neoplasms 63 secondary hyperparathyroidism 63 Lenalidomide 63 evaluating tivozanib 63 locoregional 63 Glufosfamide 63 colorectal liver metastases 63 Glioblastoma multiforme GBM 63 Tavocept 63 Nilotinib 63 ADPKD 63 operable breast cancer 63 TTR amyloidosis 63 SHPT 63 refractory chronic lymphocytic 63 Basal cell 63 advanced NSCLC 63 recurrent glioma 63 metastatic neuroendocrine tumors 63 pediatric acute lymphoblastic 63 cholangiocarcinoma 63 cutaneous T cell 62 Adjuvant Treatment 62 mutated KRAS 62 lymphoma CTCL 62 Advanced Melanoma 62 OvaRex ® MAb 62 dasatinib Sprycel ® 62 superficial bladder cancer 62 SNT-MC#/idebenone 62 non resectable 62 colorectal cancer liver metastases 62 situ CIS 62 anti EGFR antibody 62 Atypical Hemolytic Uremic Syndrome 62 Gleevec imatinib mesylate 62 MAGE A3 ASCI 62 relapsed multiple myeloma 62 Bendamustine 62 IRX 2 62 HoFH 62 Hematologic 62 hypereosinophilic syndrome 62 Clevudine 62 systemic fungal infections 62 CTAP# Capsules 62 KRAS mutation 62 Bosutinib 62 CIMZIA ™ 62 seminoma 62 PCNSL 62 acute myeloid 62 essential thrombocythemia ET 62 Acute Myeloid Leukaemia AML 62 LymphoStat B belimumab 62 cutaneous T 62 hepatitis C genotype 62 G#DT 62 plus dexamethasone 62 CMV disease 62 hormone refractory prostate cancer 62 oral FTY# 62 novel VDA molecule 62 metastatic lesions 62 Omacetaxine 62 Brentuximab Vedotin SGN 62 MALT lymphoma 62 evaluating T DM1 62 PAOD 62 unresectable 62 KRAS mutant 62 hepatorenal syndrome 62 Renal cell carcinoma 62 nasopharyngeal carcinoma 62 axitinib 62 cetuximab Erbitux ® 62 hepatitis C HCV 62 Acute myeloid leukemia AML 62 essential thrombocythemia 62 gastrointestinal stromal tumors GISTs 62 chronic eosinophilic leukemia 62 YONDELIS 62 oesophageal adenocarcinoma 62 Sezary syndrome 62 hepatoma 62 Adjuvant chemotherapy 62 KRAS mutant tumors 62 ara C 62 HCV genotype 62 unresectable locally advanced 62 Naive Patients 62 Hedgehog Pathway Inhibitor 62 grade cervical intraepithelial 62 Epratuzumab 62 refractory gout 62 oropharyngeal candidiasis OPC 62 epithelial ovarian 62 Aplidin 62 phase IIb study 62 Squamous cell 62 metastatic castration resistant 62 ELACYT 62 thalidomide Thalomid 62 stage IIIB IV 62 bone metastasis 62 UPLYSO 62 idiopathic pulmonary fibrosis IPF 62 distant metastasis 62 myelofibrosis polycythemia vera 62 Hodgkin lymphoma HL 62 allogeneic HSCT 62 Troxatyl 62 SIR Spheres 62 Vidaza ® 62 Gastric Cancer 62 sorafenib Nexavar ® 62 Mitomycin C 62 Acute myelogenous leukemia 62 chronic lymphocytic leukemia CLL 62 relapsed refractory multiple myeloma 62 histologically confirmed 62 Severe Sepsis 62 thyroid carcinoma 62 HGS ETR1 62 atypical Hemolytic Uremic Syndrome 62 endometrial cancers 62 myelofibrosis MF 62 hormone receptor negative 62 OncoVEX GM CSF 62 alvespimycin 62 Non Alcoholic Fatty 62 pancreatic neuroendocrine tumors 62 Kepivance 62 antibody MAb 62 gastric cancer 62 posterior uveitis 62 Gastric cancer 62 Gastrointestinal Stromal Tumors 62 ovarian breast 62 ZADAXIN ® 62 Degarelix 62 AA Amyloidosis 62 HRPC 62 mCRPC 62 precancerous cervical lesions 62 relapsed SCLC 62 prostate cancer HRPC 62 Renal Cell Carcinoma 62 advanced adenoma 62 hormone refractory metastatic prostate 62 Adenomas 62 BRIM2 62 oral deforolimus 62 acute promyelocytic leukemia APL 62 Gliomas 62 differentiated thyroid 62 Allovectin 7 62 taxane therapy 62 INCB# [003] 62 nonmelanoma skin cancers 62 ruxolitinib 62 fluoropyrimidine 62 MGd 62 dacarbazine DTIC 62 pancreatic lung 61 BRIM3 61 Doxil ® 61 peritoneal cancer 61 Folfox 61 hematologic malignancies 61 Chronic Lymphocytic Leukemia CLL 61 EGFR TKI 61 Advanced Renal Cell 61 ZOLINZA 61 intestinal metaplasia 61 histological subtype 61 overactive bladder syndrome 61 FOLFOX4 61 refractory cutaneous T 61 terlipressin 61 HER2 negative 61 esophageal squamous cell carcinoma 61 small lymphocytic lymphoma 61 neoadjuvant chemotherapy 61 precursor lesions 61 CIMZIA TM certolizumab pegol 61 B CLL 61 urothelial cancer 61 TheraSphere 61 grade cervical dysplasia 61 gastroesophageal junction 61 ongoing Phase 1b 61 micafungin 61 allogeneic bone marrow 61 prostate cancer CaP 61 Acute Myelogenous Leukemia AML 61 refractory chronic myeloid 61 alkylating agent 61 leukemia APL 61 brain metastases 61 refractory AML 61 neuroendocrine tumors 61 BRAF V#E mutation 61 Metastatic Melanoma 61 corticosteroid dexamethasone 61 Complicated Skin 61 Chronic Hepatitis C 61 ELOXATIN 61 endometrial carcinoma 61 mycosis fungoides 61 pemphigus vulgaris 61 malignant pleural mesothelioma MPM 61 Stage IIIb 61 medullary thyroid cancer 61 LHRH receptor positive 61 heterozygous FH 61 cell lung cancer 61 virus HCV infection 61 Diabetic Macular Edema 61 Mucositis 61 unresectable tumors 61 Follicular Lymphoma 61 Pivotal Phase III 61 ano genital warts 61 Myelodysplastic syndromes MDS 61 Erlotinib 61 advanced unresectable 61 Unresectable 61 thymoma 61 oropharyngeal candidiasis 61 squamous 61 Vidaza R 61 Squamous Cell Carcinoma 61 Hsp# Inhibitor 61 Acute Coronary Syndromes ACS 61 Surgical resection 61 CMV infection 61 nucleotide analog 61 severe oral mucositis 61 BRCA deficient 61 recurrent malignant glioma 61 adjuvant radiotherapy 61 Castration Resistant Prostate Cancer 61 HER2 + 61 Ceflatonin 61 Roche Herceptin 61 Ribavirin causes 61 proliferative diabetic retinopathy 61 gemcitabine Gemzar ® 61 smoldering myeloma 61 oligodendrogliomas 61 serous ovarian cancer 61 irinotecan chemotherapy 61 Phase #/#a trial 61 trabectedin 61 nasopharyngeal cancer 61 AEG# 61 hematologic disorders 61 Raptiva ® 61 PSADT 61 CIMZIA TM 61 Nexavar ® 61 Endometrial 61 Tyrosine Kinase Inhibitors 61 metastatic renal 61 myeloproliferative 61 HuMax EGFr 61 metastatic breast 61 chronic granulomatous disease 61 oral ridaforolimus 61 Cell Lung Cancer 61 Lymphocytic 61 Proxinium TM 61 sorafenib tablets 61 Cimzia ® certolizumab pegol 61 metachronous 61 hypoparathyroidism 61 neoplasm 61 sunitinib malate 61 minimally symptomatic metastatic castrate 61 Achieves Primary Endpoint 61 LymphoStat B TM 61 resectable 61 benign neoplasms 61 chronic periodontitis 61 mapatumumab 61 Darinaparsin 61 treatment naive genotype 61 Bezielle 61 chlamydial infections 61 imatinib resistant 61 diabetic kidney 61 Ozarelix 61 recurrent genital herpes 61 Xyfid TM 61 sorafenib Nexavar 61 Alemtuzumab 61 zalutumumab 61 metastatic colorectal carcinoma 61 lymphocytosis 61 superficial basal cell carcinoma 61 CIN2 + 61 malignancies 61 Taxotere ® 61 relapsed ovarian cancer 61 castration resistant 61 HBeAg negative patients 61 GvHD 61 Systemic Sclerosis 61 Epidermal Growth Factor Receptor 61 LUX Lung 61 chlorambucil 61 malignant lymphoma 61 Myelofibrosis 61 Metastatic 61 resected pancreatic cancer 61 Lubiprostone 61 HER2 positive breast cancer 61 SNT MC# 61 Toxicities 61 radiation sensitizer 61 TNF antagonist 61 Bronchiectasis 61 Paraplatin ® 61 pancreatic prostate 61 INCB# [001] 61 cinacalcet 61 neoadjuvant treatment 61 locoregional recurrence 61 Cimzia TM 61 Anaplastic 61 Patients Treated With 61 mutated KRAS gene 61 hepatocellular carcinoma liver 61 adjuvant radiation 61 Metastases 61 intra abdominal infections 61 Gemzar ® 61 pulmonary metastases 61 oblimersen 61 Glioblastoma 61 transarterial 61 Diffuse Large B 61 stage IIIA 61 Apaziquone 61 anterior uveitis 61 Flu Cy 61 transthyretin amyloidosis 61 biologic DMARD 61 demonstrated antitumor activity 61 TORISEL 61 anthracycline taxane 61 Prolongs Survival 60 JAK2 V#F 60 Trastuzumab 60 TEMODAL 60 oral Hycamtin 60 sarcomatoid 60 bendamustine 60 relapsed refractory AML 60 neoadjuvant therapy 60 systemic scleroderma 60 acute leukemias 60 Phase #b/#a clinical 60 chronic myeloid 60 enzastaurin 60 castration resistant prostate cancer 60 Dacogen decitabine 60 epithelial ovarian cancer 60 Decitabine 60 adriamycin 60 Catena ® 60 Virulizin ® 60 BCG refractory carcinoma 60 kidney urologic 60 cervical lesions 60 fibrotic disease 60 squamous cell 60 dirucotide MBP# 60 ErbB2 positive 60 subependymal giant cell 60 Adenocarcinoma 60 Ophena 60 cancer mCRC 60 Ischemic 60 Vectibix 60 refractory metastatic 60 Li Fraumeni Syndrome 60 Gleevec Glivec 60 EGFR mutations 60 nonmelanoma 60 APPRAISE 60 Xeloda ® 60 evaluating Prochymal 60 pain palliation 60 efalizumab 60 Golimumab 60 HDAC Inhibitor 60 BARACLUDE R 60 Prostatic 60 Leukemias 60 Endometrial cancer 60 Cloretazine 60 Sudhir Agrawal D.Phil 60 ABSSSI 60 tumor xenograft models 60 bronchogenic carcinoma 60 chemoembolization 60 HGPIN 60 randomized Phase IIb 60 metastatic kidney 60 CCR5 tropic HIV 60 rheumatoid arthritis psoriatic arthritis 60 invasive fungal infection 60 MabThera Rituxan 60 Stage IIB 60 Virologic 60 metastatic sarcomas 60 HER2 amplification 60 imatinib Gleevec 60 Lupus Nephritis 60 leukaemias 60 Diabetic Neuropathy 60 genital herpes infections 60 Fludarabine 60 Erythropoietic therapies may 60 dose cohort 60 AGILECT R 60 Clolar ® 60 MYLOTARG 60 TYZEKA 60 pituitary adenomas 60 HGS ETR2 60 Metastatic breast cancer 60 Amplimexon 60 IMA# 60 transitional cell carcinoma 60 refractory NSCLC 60 Vandetanib 60 diabetic nephropathy 60 cervical carcinoma 60 mycophenolate mofetil 60 R sorafenib tablets 60 basal cell cancers 60 NSABP C 60 basiliximab 60 EGFR HER2 60 Lupus nephritis 60 imatinib Gleevec ® 60 docetaxel Taxotere R 60 clinically localized prostate 60 lung pancreatic 60 cytoreduction 60 Nexavar tablets 60 lumiliximab 60 vinorelbine 60 decitabine 60 Chronic Prostatitis 60 Quinamed 60 severe neutropenia 60 premalignant 60 ADVEXIN 60 STRIDE PD 60 refractory Hodgkin 60 hormone receptor positive 60 TRAIL R2 60 FluCAM arm 60 HER2 expression 60 adalimumab Humira 60 HCV infection 60 galiximab 60 proliferative retinopathy 60 myelodysplastic syndromes MDS 60 metastatic cancers 60 trastuzumab DM1 T DM1 60 DOXIL 60 estramustine 60 rALLy 60 advanced metastatic renal 60 IV NSCLC 60 simplex virus 60 anti angiogenic agents 60 hypercalcemia 60 Relapsed Refractory 60 symptomatic BPH 60 thyrotoxicosis 60 T#I [002] 60 TroVax ® 60 mucinous 60 sunitinib Sutent 60 null responder 60 Barrett esophagus BE 60 Bayer HealthCare Onyx Pharmaceuticals 60 complete cytogenetic response 60 relapsed acute lymphoblastic 60 cutaneous squamous cell carcinoma 60 MabCampath 60 metastatic melanoma 60 bladder ovarian 60 leukemia CLL 60 relapsed AML 60 imatinib resistance 60 Xelox 60 trastuzumab Herceptin ® 60 Chronic Lymphocytic Leukemia 60 baseline LDH 60 MYDICAR ® 60 achieved CCyR 60 adrenocortical cancer 60 lymphoproliferative disorders 60 Colon polyps 60 lobular carcinoma 60 temsirolimus Torisel ® 60 gastrointestinal cancers 60 Anthracycline 60 Initiate Phase 60 Ph + acute lymphoblastic 60 Dasatinib 60 bortezomib Velcade 60 Malignant Glioma 60 PXD# 60 humanised monoclonal antibody 60 invasive lobular carcinoma 60 arthritis PsA 60 Hepatitis C virus HCV 60 Gorlin syndrome 60 pleural mesothelioma 60 HPV-#/# 60 invasive ductal 60 Antitumor Activity 60 Evoltra 60 hypervascular tumors 60 Panitumumab 60 Pivotal Clinical Trial 60 KRAS mutations 60 GIST tumors 60 myeloproliferative disorders 60 colorectal adenocarcinoma 60 neoplasias 60 relapsing multiple sclerosis 60 HuMax CD4 60 ZACTIMA 60 T1DM 60 BrachySil TM 60 ovarian fallopian tube 60 RhuDex R 60 Recurrences 60 CRVO 60 defibrotide 60 HBeAg positive 60 Lung transplantation 60 paclitaxel poliglumex 60 IBS C 60 biochemical relapse 60 adenomatous 60 alemtuzumab treated 60 Meets Primary Endpoint 60 Glioblastoma Multiforme 60 EGFR expressing 60 monoclonal antibody conjugated 60 depsipeptide 60 curative resection 60 chemoradiotherapy 60 paragangliomas 60 XYOTAX TM 60 imatinib mesylate 60 basal cell skin 60 EOquin TM 60 Chronic Myeloid Leukemia 60 antiangiogenic therapy 60 PROSTVAC VF 60 metaglidasen 60 diabetic gastroparesis 60 aplastic anemia AA 60 Myelodysplastic Syndrome 60 IRESSA 60 Carcinoma 60 eosinophilic asthma 60 Acute lymphoblastic leukemia 60 Idiopathic pulmonary fibrosis 60 ductal breast cancer 60 Pharmacokinetics PK 60 virological response 60 sJIA 60 PEGylated Fab fragment 60 Chronic Myelogenous Leukemia 60 associated lymphoid tissue 60 T#I mutant 60 chemotherapy cisplatin 60 pertuzumab 60 anthracycline containing 60 Tasimelteon 60 anti angiogenic therapy 60 registrational trial 60 EGFR expressing mCRC 60 microbiological eradication 59 HBeAg seroconversion 59 HCV SPRINT 59 factor receptor EGFR 59 rituximab Rituxan 59 chronic HCV infection 59 EOquin 59 Maribavir 59 vWD 59 squamous cell lung cancer 59 stage IIIb 59 Arimidex anastrozole 59 Leber Hereditary Optic Neuropathy 59 HER2 positive cancers 59 Phase 2b Clinical Trial 59 colorectal lung 59 Phenoptin 59 Annamycin 59 myelodysplastic syndromes 59 tyrosine kinase inhibitors TKIs 59 diabetes mellitus DM 59 acetonide FA 59 IV melanoma 59 Allovectin 7 ® 59 HBeAg 59 recurrent ovarian cancer 59 HSCT 59 corticosteroid therapy 59 Hycamtin ® 59 lenalidomide Revlimid R 59 endocrine therapies 59 adult chronic ITP 59 actinic keratosis 59 systemic anaplastic large 59 cisplatin resistant 59 testicular germ cell 59 EGFR mutation 59 common hematologic malignancy 59 autoantibody positive 59 cobiprostone 59 Torisel 59 HER2 overexpression 59 intraepithelial neoplasia 59 FASLODEX 59 HIV HCV coinfected 59 Tesmilifene 59 Oral Fingolimod 59 thrombocytopenic 59 CALGB # [002] 59 IL# PE#QQR 59 ixabepilone 59 allogeneic hematopoietic stem cell 59 Immunotherapeutic 59 potentially hepatotoxic 59 Medullary Thyroid Cancer 59 SUTENT 59 vemurafenib 59 Capecitabine 59 atrophic gastritis 59 cell carcinoma 59 PCa 59 Phase IIIb clinical 59 de novo AML 59 haematologic 59 breast endometrial 59 relapsed ALL 59 liver scarring 59 carcinoma 59 RSR# 59 Vidaza azacitidine 59 Voreloxin 59 Pivotal Trial 59 small molecule tyrosine 59 pegylated interferon alpha 59 Amigal 59 Alocrest 59 metastatic breast cancer 59 metastatic 59 ganetespib 59 pancreatic insufficiency 59 alpha interferons 59 anthracyclines taxanes 59 androgen deprivation 59 carcinomas 59 shingles herpes zoster 59 brivaracetam 59 severe malignant osteopetrosis 59 antibody MT# 59 lung metastases 59 microsatellite instability 59 Pooled Analysis 59 Azilect ® 59 FOLFOX chemotherapy 59 polycythemia vera PV 59 Allovectin 7 R 59 EGFR receptor 59 diagnosed glioblastoma multiforme 59 Basal cell carcinoma 59 preoperative chemotherapy 59 LOVENOX R 59 MGUS 59 Waldenstrom macroglobulinemia 59 ductal cancer 59 squamous cell carcinomas 59 Medullary thyroid cancer 59 hepatic fibrosis 59 mitomycin C 59 chronic HCV genotype 59 bevacizumab Avastin ® 59 PrevOnco ™ 59 immunotherapeutic agent 59 follicular lymphoma 59 BIBW 59 VFEND 59 abiraterone acetate 59 ThermoDox ® 59 inhibitor RG# 59 renal cell carcinomas 59 Ulcerative Colitis 59 HCV genotypes 59 papillary 59 ALT flares 59 Arranon 59 denileukin diftitox 59 uveal melanoma 59 DCVax ® Brain 59 prostate cancer PCa 59 ASCUS 59 Her2 positive 59 haematologic malignancies 59 hyperplasia BPH 59 CINTREDEKIN BESUDOTOX 59 sargramostim 59 low dose cytarabine 59 neoplasms 59 esophageal candidiasis 59 aflibercept 59 posaconazole 59 Chronic Heart Failure 59 Metastatic Renal Cell Carcinoma 59 Pivotal Phase 59 octreotide LAR 59 riociguat 59 gefitinib 59 Chronic Myelogenous Leukemia CML 59 choriocarcinoma 59 low expressors 59 pancreatic cancers 59 Hepatocellular 59 Interferon beta 1b 59 colon carcinoma 59 TYKERB 59 luteinizing hormone releasing 59 Zolinza 59 Epithelial ovarian cancer 59 Graft Versus Host 59 chemoresistant 59 adjuvant tamoxifen 59 premalignant lesions 59 somatostatin analogues 59 Bayer Nexavar 59 Virulizin R 59 colorectal carcinomas 59 papillary RCC 59 liver resection 59 Glioma 59 contralateral breast 59 Neoadjuvant 59 urothelial bladder cancer 59 Enzastaurin 59 chemotherapy induced neutropenia 59 recurrent VTE 59 FLT3 59 PROCHIEVE ® 8 59 GW# [003] 59 leiomyosarcoma 59 Gliadel Wafer 59 Albuferon TM 59 lung fibrosis 59 HCV infections 59 T Cell Lymphoma 59 Azedra 59 prostate cancer mCRPC 59 EFAPROXYN 59 underwent resection 59 ATTR CM 59 Haptoglobin